When the FDA approved Fayuvi for Sanfilippo syndrome type A on September 17th, 2026, the first question many parents asked was not whether it worked. It was what it would cost. Analysts reported a price of $3.95 million (BioSpace, 2026), which puts it level with Kebilidi and just behind the most expensive medicine ever sold in the United States, Lenmeldy, at $4.25 million (ICER, 2025).
Numbers like that are real, and they shape which therapies survive. They are also not the number that lands on a family's kitchen table. This guide separates the two: what gene therapies cost the health system, and what it takes for a patient to actually receive one.
Gene Therapy Prices in 2026, From $250,000 to $4.25 Million
Every gene therapy below is a one-time treatment. The price is the US list price, called the wholesale acquisition cost, before the confidential discounts and rebates that insurers negotiate. Most companies announce their price at approval; a few, like PTC for Kebilidi, never publicize it, and the figure comes from pricing databases instead.
Manufacturers justify these prices by arguing that a single infusion replaces a lifetime of care, such as years of factor replacement for hemophilia B or repeated spinal injections for spinal muscular atrophy. The Institute for Clinical and Economic Review (ICER), an independent group that estimates what a drug's benefit is worth, has usually landed below the list price, sometimes only slightly. Its 2023 review of the 2 sickle cell disease gene therapies shows how far apart 2 treatments for the same disease can sit.
Who Pays for Gene Therapy: Insurance, Medicaid and the Out-of-Pocket Cap
For a family with commercial insurance, the question is coverage, not cost. Once an insurer approves a gene therapy, the family pays up to the plan's deductible and coinsurance and then stops at the out-of-pocket maximum. With a bill this size, a family generally reaches that ceiling quickly. Manufacturer copay programs, where a family qualifies, can cover much of the rest.
Getting to yes is slower. Insurers write a coverage policy for each new therapy. A Tufts Medical Center review of cell and gene therapy policies from 18 of the largest US commercial insurers found that about half added requirements beyond the FDA label, such as extra clinical or genetic criteria, although most of those matched who had been studied in the trials (Chambers et al., JAMA, 2025). New approvals can also sit with no policy at all: 6 months after Kebilidi's approval, 44% of commercial plans had not written one yet (ICER, 2025). No published study reliably measures how long prior authorization takes for gene therapy, so be wary of anyone quoting a precise number of weeks.
Medicaid and the CMS Cell and Gene Therapy Access Model
Medicaid must cover FDA-approved drugs, but states have wide latitude over the rules around them. For sickle cell disease, the federal government stepped in. Under the Cell and Gene Therapy Access Model, the Centers for Medicare & Medicaid Services (CMS) negotiated one set of outcomes-based terms for Casgevy and Lyfgenia on behalf of the states. If a treated patient does worse than expected, the manufacturer pays part of the cost back.
As of CMS's latest update, 32 states plus Washington, D.C. and Puerto Rico take part, covering about 84% of people with sickle cell disease on Medicaid. The model applies to sickle cell only. CMS says it is exploring other conditions but has not named any, so a Medicaid family seeking gene therapy for hemophilia, SMA or Duchenne still goes through their own state's process.
Gene Therapy Patient Support Programs and Travel Help
Gene therapies are given only at a small number of qualified treatment centers, which often means a long trip and, for cell-based therapies like Casgevy or Lyfgenia, weeks near the hospital. Every manufacturer runs a support program with a case manager who checks insurance, handles prior authorization paperwork and, for most programs, helps with travel and lodging for eligible patients. These programs are free and do not depend on income.
- Zolgensma and Itvisma (Novartis)
- Novartis Patient Support. A case coordinator handles insurance and appeals, and eligible commercially insured patients can use copay assistance.
- Casgevy (Vertex)
- Vertex Connects. A care manager coordinates logistics, with travel and lodging help for eligible patients.
- Hemgenix (CSL Behring)
- HEMGENIX Connect. A patient navigator and case manager, copay support for eligible commercially insured patients, and travel and logistics help.
- Elevidys (Sarepta)
- SareptAssist, at 1-888-727-3782, for logistics and insurance navigation.
- Lenmeldy (Orchard, a Kyowa Kirin company)
- Orchard Assist. Benefits checks, prior authorization help, out-of-pocket estimates, and a review of whether your plan covers travel and lodging.
- Lyfgenia, Zynteglo and Skysona (Genetix, formerly bluebird bio)
- Genetix CARES, formerly called my bluebird support. Travel and lodging, financial assistance and fertility preservation support.
- Fayuvi and Genglycos (Ultragenyx)
- UltraCare, with dedicated Gene Therapy Guides, at 888-756-8657.
Ask the treatment center's financial counselor as well. Centers that give gene therapy regularly have handled these approvals before and usually know which of your insurer's requirements trip families up.
Gene Therapy Warranties and Outcomes-Based Agreements
Because a one-time price is paid before anyone knows how long the benefit lasts, several companies promise money back if the therapy underdelivers. These deals are between the manufacturer and the insurer, so they protect the health system rather than the family directly, but they make insurers more willing to approve.
Zynteglo's maker refunds up to 80% of the cost if a patient does not become and stay free of blood transfusions for up to 2 years (bluebird bio SEC filing, 2022). Hemgenix's maker, CSL Behring, has said it refunds a substantial but undisclosed share if a patient goes back on regular factor IX treatment within 4 years (Cell & Gene, 2023). Zolgensma launched with 5-year outcomes-based agreements and a pay-over-time option (Novartis, 2019), and Zevaskyn's price includes a partial refund if a patient needs more treatment.
Gene Therapies Withdrawn for Lack of Buyers, From Beqvez to Roctavian
A high price only matters if someone pays it, and 2 gene therapies have now left the US market for commercial reasons rather than safety ones. Pfizer stopped selling Beqvez for hemophilia B in February 2025, after no patient had been treated commercially (BioPharma Dive, 2025). BioMarin withdrew Roctavian for hemophilia A in 2026 after failing to find a buyer, and it stopped being available at the end of May (BioMarin, 2026). Earlier, bluebird bio pulled Zynteglo and Skysona from Europe in 2021 after a pricing dispute in Germany.
bluebird itself, whose therapies worked and whose market value once topped $11 billion, sold to private equity firms Carlyle and SK Capital in 2025 for under $30 million in upfront cash (STAT, 2025) and now operates as Genetix Biotherapeutics. Its Lyfgenia, Zynteglo and Skysona remain available in the US, though the FDA narrowed Skysona's label in August 2025 after blood cancers were diagnosed in 10 of 67 trial patients (FDA, 2025).
For patients, the lesson from these withdrawals is practical. A therapy approved for your condition is only an option while someone is still making and selling it, and people already treated keep their follow-up care: BioMarin, for one, has said it will continue monitoring Roctavian patients and honoring its refund agreements.
One email when trials change or decisions land for the conditions you care about. No newsletter, no spam.
Questions Families Ask About Gene Therapy Costs
How much does gene therapy cost in 2026?
US list prices for approved gene therapies range from about $250,000 (Encelto) to $4.25 million (Lenmeldy), and most fall between $2 million and $4 million. Fayuvi and Kebilidi are reported at $3.95 million. These are list prices before confidential discounts, and they are paid by insurers or Medicaid, not by families.
Will my insurance cover gene therapy?
Most large insurers cover FDA-approved gene therapies for patients who meet their policy's criteria, but many policies add requirements beyond the FDA label, and very new approvals may not have a policy yet. The manufacturer's patient support program and the treatment center's financial counselor can check your plan and handle prior authorization for you.
How much will I pay out of pocket for gene therapy?
With insurance, your share is limited by your plan's yearly out-of-pocket maximum. For 2026 Marketplace plans that cap is $10,600 for an individual and $21,200 for a family. Manufacturer copay programs may reduce it further for eligible commercially insured patients. Travel and lodging are separate costs, and most manufacturer programs help with them.
Does Medicaid cover gene therapy for sickle cell disease?
In most states, yes. Under the CMS Cell and Gene Therapy Access Model, 32 states plus Washington, D.C. and Puerto Rico cover Casgevy and Lyfgenia for Medicaid patients under outcomes-based terms negotiated by CMS, reaching about 84% of people with sickle cell disease on Medicaid. Other states handle coverage through their own Medicaid process.
What is the most expensive drug in the world?
In the United States, the highest list price is Lenmeldy, a one-time gene therapy for metachromatic leukodystrophy, at $4.25 million. Fayuvi and Kebilidi follow at $3.95 million each.
If you are weighing a clinical trial instead of an approved therapy, trial sponsors pay for the treatment itself, and many cover travel too. Our guide to the hidden costs of clinical trials walks through what they usually do and do not cover.